Cancer Genetics, Inc. (CGIX) - Product Pipeline Analysis, 2013 Update - New Market Study Published
New Medical Devices research report from GlobalData is now available from Fast Market Research
Boston, MA -- (SBWire) -- 01/20/2014 --Cancer Genetics, Inc. (CGI) is a pharmaceutical company. The company offers DNA-based cancer diagnostics products and services. Its products include MatBA, UroGenRA, and FHACT. CGI's MatBA is a mature b-cell neoplasm array used in diagnosis and prognosis of non-Hodgkin lymphomas. The company's UroGenRA is an oligonucleotide array product that is developed to detect genomic copy number alterations with prognostic and diagnostic value in kidney, prostate and bladder cancers. Its FHACT is a FISH-based HPV-associated cancer test. The company provides clinical services such as test menu, complete program, and summation report. It collaborates with Memorial Sloan-Kettering, The Cleveland Clinic, Mayo Clinic and the National Cancer Institute. CGI is headquartered in New Jersey, the US.
View Full Report Details and Table of Contents
This report is a source for data, analysis and actionable intelligence on the Cancer Genetics, Inc. portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, the development stage, trial phase, product milestones, pipeline territory, estimated approval date, and estimated launch date.
Each pipeline product is profiled to cover information on product description, function, technology, indication, and application. The report is also supplemented with a detailed company profile and information on clinical trials, wherever applicable.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.
- Detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments.<\li> - Detailed coverage on all the pipeline products, by equipment type, by therapy area, by development stage, and by trial phase.<\li> - Information on product milestones and pipeline territory for each product, the estimated approval date, and estimated launch date.<\li> - Profile of each pipeline product with additional information on product description, function, technology, indication(s), and application.<\li> - Data on relevant clinical trials and product patent details, wherever applicable.<\li> - Information on clinical trial, wherever applicable, is supplemented with information on trial phase, trial status, trial objective, trial design, target patients, unique physician identifier, primary point, secondary point, acronym, participants inclusion, participants exclusion, interventions, trial results, trial start date, trial end date, study type, trial site, trial funding, age eligibility, and gender eligibility.
Reasons to Get This Report
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape globally.<\li> -
Companies Mentioned in this Report: Cancer Genetics, Inc. (CGIX)
About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.
Browse all Medical Devices research reports at Fast Market Research
You may also be interested in these related reports:
- Myriad Genetics, Inc. (MYGN) - Product Pipeline Analysis, 2013 Update
- Cepheid (CPHD) - Product Pipeline Analysis, 2013 Update
- MDxHealth SA (MDXH) - Product Pipeline Analysis, 2013 Update
- bioMerieux S.A. (BIM) - Product Pipeline Analysis, 2013 Update
- BSD Medical Corporation (BSDM) - Product Pipeline Analysis, 2013 Update
- Rosetta Genomics, Ltd. (ROSG) - Product Pipeline Analysis, 2013 Update
- AngioDynamics, Inc. (ANGO) - Product Pipeline Analysis, 2013 Update
- GenomicTree, Inc. - Product Pipeline Analysis, 2013 Update
- XEPTAGEN SpA - Product Pipeline Analysis, 2013 Update
- Philips Healthcare - Product Pipeline Analysis, 2013 Update
Media Relations Contact
Director of Marketing
View this press release online at: http://rwire.com/439982